-
公开(公告)号：US12130286B2
公开(公告)日：2024-10-29
申请号：US17806109
申请日：2022-06-09
申请人： Shahrzad Forouzanfar , Iman Khakpour , Nezih Pala , Chunlei Wang
发明人： Shahrzad Forouzanfar , Iman Khakpour , Nezih Pala , Chunlei Wang
IPC分类号： G01N33/543 , G01N27/30 , G01N27/327 , G01N33/574
CPC分类号： G01N33/5438 , G01N27/308 , G01N27/3276 , G01N33/57484 , G01N2333/49
摘要： Biosensors capable of detecting certain biomarkers (e.g., platelet-derived growth factor-BB (PDGF-BB)), as well as methods of fabricating the same and methods of using the same, are provided. The biosensors can be disposable and/or label-free. Electrochemical bipolar exfoliation can be used to exfoliate, reduce, and deposit (in a single step) graphene nanosheets on a desired substrate (e.g., an electrode). Affinity aptamers can be immobilized on the graphene nanosheets disposed on the substrate.
-
公开(公告)号：US12122822B2
公开(公告)日：2024-10-22
申请号：US16758930
申请日：2020-02-12
申请人： MEDPACTO, INC.
发明人： Seong Jin Kim , Dong Woo Kang
IPC分类号： C07K16/18 , A61P35/00 , C12N15/63 , G01N33/574 , G01N33/68
CPC分类号： C07K16/18 , A61P35/00 , C12N15/63 , G01N33/57484 , G01N33/6854 , C07K2317/24 , C07K2317/565 , G01N2333/4703
摘要： The present application discloses an antibody or antigen-binding fragment thereof that binds specifically to a BAG2 polypeptide or fragment thereof, and a method of treating cancer thereof.
-
3.发明公开公开(公告)号：US20240344132A1
公开(公告)日：2024-10-17
申请号：US18134125
申请日：2023-04-13
IPC分类号： C12Q1/6886 , C12Q1/6869 , G01N33/569 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q1/6869 , G01N33/56972 , G01N33/57484 , C12Q2600/158
摘要： This technology relates to a method of treating a liver cancer, and a method of predicting a response of a subject suffering from liver cancer to a treatment with an immune checkpoint inhibitor. This technology further relates to a method of predicting a treatment-induced immune-related adverse events (irAEs) of a subject suffering from liver cancer to a treatment with an immune checkpoint inhibitor.
-
公开(公告)号：US20240327491A1
公开(公告)日：2024-10-03
申请号：US18576468
申请日：2022-07-11
IPC分类号： C07K14/725 , A61K39/00 , A61P35/00 , C12N5/0783 , G01N33/574
CPC分类号： C07K14/7051 , A61K39/4611 , A61K39/4632 , A61K39/464401 , A61P35/00 , C12N5/0636 , G01N33/57484 , A61K2239/31 , C12N2510/00 , G01N2333/7051
摘要： This disclosure describes novel T cell receptors (TCRs) specific for tumor-associated antigens (TAAs) and methods of use thereof. The disclosed TCRs and methods of use expand the applications of adoptive cell therapy and TCR-based cellular immunotherapies.
-
公开(公告)号：US20240319195A1
公开(公告)日：2024-09-26
申请号：US17769245
申请日：2020-10-15
申请人： CORNELL UNIVERSITY
发明人： David C. LYDEN , Goncalo RODRIGUES
IPC分类号： G01N33/574 , A61K39/00 , A61P35/04 , C07K16/18 , C12Q1/6886
CPC分类号： G01N33/57484 , A61P35/04 , C07K16/18 , C12Q1/6886 , A61K2039/505 , C07K2317/76 , C07K2317/92 , C12Q2600/118 , C12Q2600/158
摘要： The present disclosure is directed to a method that involves selecting a subject having a primary tumor and obtaining, from the selected subject, a sample containing exosomes derived from primary tumor cells. The exosomes are isolated from the sample and expression levels of cell migration-inducing and hyaluronan-binding protein (CEMIP) are detected in the isolated exosomes.
-
公开(公告)号：US12098193B2
公开(公告)日：2024-09-24
申请号：US16754877
申请日：2018-10-09
IPC分类号： C07K16/22 , A61K38/21 , C07K16/28 , G01N33/574
CPC分类号： C07K16/22 , A61K38/217 , C07K16/2818 , C07K16/2827 , G01N33/57484 , G01N2800/7028 , G01N2800/7052
摘要： The present disclosure provides methods of inducing desmoplastic stroma to express a normal phenotype by detecting increased levels of NetG1 or NGL1 in tumor or in desmoplastic stroma isolated from a human subject, and/or detecting NetG1 in circulating extracellular vesicles, and/or detecting increased pFAK in the stroma, and treating the human subject with a therapeutic regimen; and by detecting NetG1 in a microvesicle isolated from a human subject, and/or treating the human subject with a therapeutic regimen.
-
公开(公告)号：US20240302377A1
公开(公告)日：2024-09-12
申请号：US18433891
申请日：2024-02-06
发明人： Anton Wellstein
IPC分类号： G01N33/574 , C12Q1/68 , C12Q1/6886 , G01N33/68
CPC分类号： G01N33/57492 , C12Q1/68 , C12Q1/6886 , G01N33/57484 , G01N33/6848
摘要： The present invention provides methods of identifying neopeptides in abnormal cells, with the methods comprising sequencing long-read messenger RNA (mRNA) isolated from the abnormal cells, identifying splice variants that could be generated from the sequenced long-read mRNA, determining if the abnormal cells contain neopeptides that correlate with the identified splice variants. The methods may also comprise identifying at least one neoantigen on the neopeptides that are present in the abnormal cells.
-
公开(公告)号：US20240293364A1
公开(公告)日：2024-09-05
申请号：US18548522
申请日：2022-03-04
IPC分类号： A61K31/4035 , A61K31/502 , A61K31/5025 , A61P35/00 , G01N33/574
CPC分类号： A61K31/4035 , A61K31/502 , A61K31/5025 , A61P35/00 , G01N33/57484 , G01N2333/9108
摘要： The invention provides DNA damage response (DDR) pathway genes and their gene products as biomarkers to predict effective treatment of cancer using an MDM2 antagonist. Identifying one or more DDR pathway biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an MDM2 antagonist. Accordingly, the invention relates generally to a companion diagnostic for MDM2 antagonist therapy. In particular, the DDR pathway comprises one or more genes from: the homologous recombination repair (HRR) pathway; the non-homologous end joining (NHEJ) pathway; the mismatch repair (MMR) pathway; the Fanconi
-
公开(公告)号：US20240272161A1
公开(公告)日：2024-08-15
申请号：US18568444
申请日：2022-06-09
发明人： Janis M. Taube , Sandor Szalay , Andrew M. Pardoll , Elizabeth L. Engle , Sneha Berry , Benjamin Green
IPC分类号： G01N33/574 , G01N33/58 , G01N33/68
CPC分类号： G01N33/57484 , G01N33/57423 , G01N33/5743 , G01N33/582 , G01N33/6854 , G01N2333/70517 , G01N2333/70596 , G01N2800/52
摘要： Provided herein are method of predicting a subject's response to immunotherapy that include (a) staining a biological sample disposed on a substrate: (b) imaging the biological sample, wherein one or more image(s) of a high-power field (HPF) is generated: (c) detecting multiple biomarkers in the biological sample; and (d) analyzing the one or more image(s), thereby predicting the subject's response to immunotherapy.
-
公开(公告)号：US20240269179A1
公开(公告)日：2024-08-15
申请号：US18466966
申请日：2023-09-14
IPC分类号： A61K35/17 , A61K39/39 , A61P35/00 , C07K14/74 , C12Q1/68 , C12Q1/6869 , C12Q1/6881 , C12Q1/6886 , G01N33/569 , G01N33/574 , G16B30/00
CPC分类号： A61K35/17 , A61K39/39 , A61P35/00 , C07K14/70539 , C12Q1/68 , C12Q1/6869 , C12Q1/6881 , C12Q1/6886 , G01N33/56977 , G01N33/57484 , C12Q2600/106 , C12Q2600/156 , G16B30/00
摘要： Disclosed are methods of identifying target epitopes for a tumor of an individual using massively parallel sequencing and analyzing mutant epitopes. Also disclosed are methods of treating a tumor in an individual. Also disclosed are personalized, anti-tumor immunogenic preparations (e.g., personalized, anti-tumor chimeric antigen receptors (CAR) or chimeric antigen receptor T cell (CAR T cell)) customized for an individual cancer patient who initially responded to anti-tumor therapy and later became resistant to the therapy.
-
-
-
-
-
-
-
-
-
搜索结果
4127 条记录 (耗时 0.044 秒)
